Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Homology Medicines Inc (FIXX).
Homology Medicines, Inc. has successfully completed a merger with Legacy Q32, with Legacy Q32 surviving as a wholly-owned subsidiary, transforming Homology into Q32 Bio Inc., a clinical-stage biotech company. Following the merger, a reverse stock split was executed at a 1:18 ratio, and Homology’s stockholders approved a significant issuance of common stock to Legacy Q32’s stockholders. Post-merger, the combined entity’s focus is on developing treatments for autoimmune and inflammatory diseases. The company’s stock commenced trading under the new ticker symbol “QTTB” on The Nasdaq Capital Market.
For a thorough assessment of FIXX stock, go to TipRanks’ Stock Analysis page.